Description: Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.
Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.
Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.
MCE offers a unique collection of 1816 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.
MCE Anti-Liver Cancer Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 1778 compounds supplied in 10 mM solution, 37 compounds supplied in 2 mM solution and 1 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.
Advantages:
- A unique collection of 1816 compounds with identified and potential anti-liver cancer activity for high throughput screening (HTS) and high content screening (HCS).
- A useful tool for the discovery of anti-liver cancer drugs.
- Target diverse, medicinally active and cell permeable.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
- More detailed compound information with structure, IC50, and other chemical & biological data.
- High purity and quality validated by NMR and LC/MS.
Formulation: A collection of 1816 anti-liver cancer compounds supplied as pre-dissolved Solutions or SolidSolution:1778 compounds supplied in 10 mM solution,37 compounds supplied in 2 mM solution,1 compounds supplied in 3 mg/mL solution.
Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.
Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
English
Deutsch
